AAA817
Phase 3Small molecule
NovartisAAA817 is one of 45 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Antiandrogen Therapy
UUniversity of Washington
Phase 3
Triptorelin Embonate
IpsenPhase 3
Lhrha
Johnson & JohnsonPhase 3
Docetaxel /m²
AstraZenecaPhase 3
Luteinizing Hormone Releasing Hormone
UUS Department of Veterans Affairs
Phase 3
AAA817
NovartisPhase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Targeted Therapy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AAA817. EMBL-EBI & Wellcome Sanger Institute.
- [4]